MarginsXMarginsX
Home › Markets › Health Care › EMIS

Emmis Acquisition Corp. (EMIS)

EMIS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$10.34
+0.10% on the day
Market cap
Market cap not reported by the Nasdaq screener
Revenue
Blank-check company: no operating revenue
Net income
Blank-check company: no operating revenue

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerEMIS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2025
SEC CIK0002075816
SEC industry codeBlank Checks
Incorporated inCayman Islands

Financials

Blank-check company: no operating revenue.

Warning signs

Cash runway
17.7 months
$708K cash at June 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
Yes
10-Q filed August 6, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"However, because the Company is required to complete its initial Business Combination or obtain an extension of the Combination Period by March 26, 2027, which falls within one year from the date these condensed financial statements are issued, or otherwise cease operations and liquidate, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern."
10-Q 2026-08-06
Cash and burn$708K cash; operating cash flow -$120K a quarter.Report 2026-06-30
Shares outstanding15,775,833 (2026-07-31).Cover page 2026-07-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
Delisting25-NSE filed25-NSE 2025-10-21
AuditorTAAD LLP, Diamond Bar, California, United StatesPCAOB Form AP 2026-03-28
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed$749K-$77K$708KNo debt tagsNeeds four quarters10-Q 2026-08-06
Q2 2026
2026-03-31
Not filed$973K-$162K$782KNo debt tagsNeeds four quarters10-Q 2026-08-06
Q4 2025
2025-12-31
Not filed$933KNot filed$948KNo debt tagsNeeds four quarters10-K 2026-03-27
Q3 2025
2025-09-30
Not filed-$70KNot filed$1.4MNo debt tagsNeeds four quarters10-Q 2025-11-13
Q2 2026
2025-06-30
Not filed-$23KNot filed$0$34KNeeds four quarters10-Q 2026-08-06

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS
424B42025-09-26
Latest annual report
ANNUAL REPORT
10-K2026-03-27
Latest quarterly / interim
QUARTERLY REPORT
10-Q2026-11-16
Latest current report
CURRENT REPORT
8-K2026-09-28

Source: SEC EDGAR submissions feed, 49 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-0.1%
1 month+0.5%
3 months+1.1%
Year to date+3.8%
1 year+3.8%
From 52-week high-0.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Other listings for this company

TickerNamePrice
EMISREmmis Acquisition Corp. Rights$0.0700

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
MLTXMoonLake Immunotherapeutics$11.73-6.16%$998.3M
CYRXCryoPort Inc.$19.80-0.45%$1.0B
SVRASavara Inc.$4.46-3.77%$985.1M
SPTXSeaport Therapeutics Inc.$19.12-4.30%$1.0B
JBIOJade Biosciences Inc.$15.34-4.99%$975.3M
VSTMVerastem Inc.$7.70-5.87%$970.3M
MTRIMentari Therapeutics Inc.$19.87+6.83%$1.0B
ANROAlto Neuroscience Inc.$27.12-8.19%$1.1B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier